Here’s Who I Think Will Win the AI Chip War
JHVEPhoto / iStock Editorial via Getty Images Alphabet (GOOG) launched Gemini 3.0 to strong reception and prompted OpenAI…
Warren Buffett Bets Big on AI — He Just Bought 17,846,142 Shares of This Legendary Tech Stock
Warren Buffett is stepping down as head of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) at the end of 2025.…
One Just Partnered With Nvidia)
Billionaire Bill Ackman runs Pershing Square, a hedge fund that beat the S&P 500 by 24 points in…
25% of Warren Buffett’s Portfolio Is Invested in These 3 Unstoppable AI Stocks
Berkshire Hathaway’s portfolio owns at least three leading tech stocks that are benefiting from AI. All three of…
Google DeepMind’s AlphaFold shows why science may be AI’s killer app
While many businesses continue to seek AI’s killer app, biochemists have already found it. That application is protein…
How Google Dodged the AI Search Collapse
Google Search was supposed to lose ground in the artificial intelligence (AI) era, but Alphabet’s third-quarter 2025 earnings…
Alphabet’s AI-Related Offerings Help Drive Stock to Record High
Alphabet’s stock rose to a record high and moved the company closer to a $4 trillion valuation on…
3 Artificial Intelligence Stocks You Can Buy and Hold for the Next Decade
Alphabet has proven it’s an artificial intelligence (AI) force to be reckoned with. Amazon’s cloud computing and advertising…
The Best AI Stocks to Invest $5,000 in Right Now
Palantir continues to show incredible momentum, expanding across the U.S. commercial sector. Alphabet is well-positioned to benefit from…
Billionaire Stanley Druckenmiller Just Bought These 3 AI Stocks. Should Investors Follow Suit?
Amazon has been a low-key artificial intelligence winner. Meta Platforms is the cheapest of the “Magnificent Seven” stocks…
‘Agentic’ AI is a buzzword made up of marketing fluff and real promise
For technology adopters looking for the next big thing, “agentic AI” is the future. At least, that’s what…
AbbVie parts ways with Calico
Unexpected uncoupling raises questions about the pace – and patience – of longevity drug discovery amid shifting pharma…